295 related articles for article (PubMed ID: 25888926)
1. New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells.
Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
Biochem Pharmacol; 2015 Jun; 95(3):133-44. PubMed ID: 25888926
[TBL] [Abstract][Full Text] [Related]
2. Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands.
Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
J Inorg Biochem; 2014 Nov; 140():72-9. PubMed ID: 25063910
[TBL] [Abstract][Full Text] [Related]
3. Novel trans-platinum complexes of the histone deacetylase inhibitor valproic acid; synthesis, in vitro cytotoxicity and mutagenicity.
Griffith DM; Duff B; Suponitsky KY; Kavanagh K; Morgan MP; Egan D; Marmion CJ
J Inorg Biochem; 2011 Jun; 105(6):793-9. PubMed ID: 21497577
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates.
Novohradsky V; Zanellato I; Marzano C; Pracharova J; Kasparkova J; Gibson D; Gandin V; Osella D; Brabec V
Sci Rep; 2017 Jun; 7(1):3751. PubMed ID: 28623355
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin.
Zajac J; Kostrhunova H; Novohradsky V; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
J Inorg Biochem; 2016 Mar; 156():89-97. PubMed ID: 26780576
[TBL] [Abstract][Full Text] [Related]
6. Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt(NH3)2malSAHA-2H)].
Brabec V; Griffith DM; Kisova A; Kostrhunova H; Zerzankova L; Marmion CJ; Kasparkova J
Mol Pharm; 2012 Jul; 9(7):1990-9. PubMed ID: 22591133
[TBL] [Abstract][Full Text] [Related]
7. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.
Eikel D; Lampen A; Nau H
Chem Res Toxicol; 2006 Feb; 19(2):272-8. PubMed ID: 16485903
[TBL] [Abstract][Full Text] [Related]
8. HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells.
Ganai SA; Kalladi SM; Mahadevan V
J Biomol Struct Dyn; 2015; 33(6):1185-97. PubMed ID: 25012937
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells.
Alessio M; Zanellato I; Bonarrigo I; Gabano E; Ravera M; Osella D
J Inorg Biochem; 2013 Dec; 129():52-7. PubMed ID: 24080480
[TBL] [Abstract][Full Text] [Related]
10. An Anticancer Pt
Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
[TBL] [Abstract][Full Text] [Related]
11. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
Groh T; Hrabeta J; Khalil MA; Doktorova H; Eckschlager T; Stiborova M
Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435
[TBL] [Abstract][Full Text] [Related]
12. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
13. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.
Marchion DC; Bicaku E; Daud AI; Sullivan DM; Munster PN
Cancer Res; 2005 May; 65(9):3815-22. PubMed ID: 15867379
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
Kwiecińska P; Wróbel A; Taubøll E; Gregoraszczuk EŁ
Toxicol Lett; 2014 Jan; 224(2):225-32. PubMed ID: 24200999
[TBL] [Abstract][Full Text] [Related]
15. Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cells.
Almotairy ARZ; Montagner D; Morrison L; Devereux M; Howe O; Erxleben A
J Inorg Biochem; 2020 Sep; 210():111125. PubMed ID: 32521289
[TBL] [Abstract][Full Text] [Related]
16. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
Xu Z; Hu W; Wang Z; Gou S
Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells.
Lin CT; Lai HC; Lee HY; Lin WH; Chang CC; Chu TY; Lin YW; Lee KD; Yu MH
Cancer Sci; 2008 Jun; 99(6):1218-26. PubMed ID: 18429963
[TBL] [Abstract][Full Text] [Related]
18. ctc-[Pt(NH
Li Y; Shi S; Zhang S; Gan Z; Wang X; Zhao X; Zhu Y; Cao M; Wang X; Li W
Dalton Trans; 2021 Aug; 50(32):11180-11188. PubMed ID: 34338267
[TBL] [Abstract][Full Text] [Related]
19. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
20. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
